Illumina (ILMN) · Life Sciences
Illumina Q2 FY2026 earnings: summary, key numbers & outlook
Results filed 30 Jul 2026 · Quarter ended 28 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
Illumina's NovaSeq X demand stayed high with more than 95 placements, while clinical customers expanded sequencing use and the company added spatial and multiomics offerings.
Clinical customers drove the quarter, as Illumina says its technology is letting them expand sequencing-intensive applications. NovaSeq X demand stayed high more than three years after launch, with more than 95 placements. Clinical markets make up approximately 65% of sequencing consumables revenue. This summer Illumina launched StrataMap Spatial, a sequencing-based spatial workflow, and biopharma interest is growing with over 300 million cells delivered to date.
Management is steering Illumina toward a broader multiomics ecosystem built on NovaSeq X, with a strategy of delivering the highest quality insights at the lowest end-to-end cost. The tension is execution and cost. Integrating the SomaLogic business and managing proteomics partners is a stated risk, supply investments carry real costs that Illumina is partly sharing with customers, and its place on China's Unreliable Entities List and U.S. tariffs add uncertainty.
No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.
Key numbers
- Revenue · GAAP
- $1.16 billion
- Net income · GAAP
- $207.0M
- Diluted EPS · GAAP
- $1.35
- Diluted EPS · non-GAAP
- $1.31
- Gross margin · GAAP
- 66.4%
- Gross margin · non-GAAP
- 68.2%
- Operating income · GAAP
- $245.0M
- Operating margin · GAAP
- 21.1%
up 9.5% from Q2 2025
from $235 in Q2 2025
from $1.49 in Q2 2025
from $1.19 in Q2 2025
from 65.6% in Q2 2025
from 69.4% in Q2 2025
from $214 in Q2 2025
from 20.2% in Q2 2025
| Segment or metric | Value | Change |
|---|---|---|
| Product revenue | $982.0M | from $912 in Q2 2025 |
| Service and other revenue | 177.0M | from 147 in Q2 2025 |
| ROW organic revenue growth | 8.1% | excludes currency, acquisitions and China |
Where each number comes from
- Revenue: “Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China”
- Net income: “Income before income taxes | 260 | 306 | 417 | 488 Provision for income taxes | 53 | 71 | 77 | 122 Net income | $207 | $235 | $340 | $366”
- Diluted EPS: “GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% •GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31”
- Diluted EPS: “GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% •GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31”
- Gross margin: “Gross margin | 66.4% | 65.6% | 68.2% | 69.4% Operating profit | $245 | $214 | $260 | $252 Operating margin | 21.1% | 20.2% | 22.5% | 23.8%”
- Gross margin: “Gross margin | 66.4% | 65.6% | 68.2% | 69.4% Operating profit | $245 | $214 | $260 | $252 Operating margin | 21.1% | 20.2% | 22.5% | 23.8%”
- Operating income: “Gross margin | 66.4% | 65.6% | 68.2% | 69.4% Operating profit | $245 | $214 | $260 | $252 Operating margin | 21.1% | 20.2% | 22.5% | 23.8%”
- Operating margin: “GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% •GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31”
- Product revenue: “Revenue: Product revenue | $982 | $912 | $1,899 | $1,793 Service and other revenue | 177 | 147 | 352 | 307 Total revenue | 1,159 | 1,059”
- Service and other revenue: “Revenue: Product revenue | $982 | $912 | $1,899 | $1,793 Service and other revenue | 177 | 147 | 352 | 307 Total revenue | 1,159 | 1,059”
- ROW organic revenue growth: “Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
| From the filing | Q2 FY2026 | vs year ago | vs last quarter |
|---|---|---|---|
| Revenue | $1.2B | +9.4% | +6.2% |
| Operating income | $245.0M | +14.5% | +17.2% |
| Net income | $207.0M | −11.9% | +54.5% |
| Diluted EPS | $1.35 | −9.4% | +55.2% |
| Free cash flow | $161.0M | −21.1% | −35.9% |
| Gross margin | 66.4% | +0.8 pts | +0.3 pts |
| Operating margin | 21.1% | +0.9 pts | +1.9 pts |
Calculated by code from XBRL, not by the model.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Total revenue | fiscal year 2026 | $4.60-$4.64 billion |
| ROW organic revenue growth | fiscal year 2026 | greater than 5% |
| Non-GAAP operating margin | fiscal year 2026 | 23.4%-23.6% |
| Non-GAAP diluted EPS | fiscal year 2026 | $5.30-$5.40 |
Key takeaways
NovaSeq X demand remains high after three years
More than 95 NovaSeq X placements in the quarter show demand holding well beyond launch. Management says this demand continues as it expands workflow and multiomics capabilities.
Clinical customers are the main growth engine
Clinical markets, about 65% of sequencing consumables revenue, remained the primary growth driver. Management says its technology lets clinical customers expand sequencing-intensive applications.
StrataMap Spatial extends Illumina into spatial biology
Illumina launched StrataMap Spatial, a sequencing-based spatial workflow, this summer. With over 300 million cells delivered to date, biopharma interest continues to grow.
Multiomics is the second leg of strategy
Management frames the strategy as the highest quality insights at the lowest end-to-end cost, with multiomics as the next step. The release points to the SomaLogic business and proteomics as part of that push.
Supply investments are rising and costs are shared
Illumina made significant progress on supply investments in the quarter. Management says those costs are real and that it is sharing some of the increase with customers.
Charts
Fourth quarter worked out from the annual figure.
Data
| Q4 FY24 | $1.1B * |
| Q1 FY25 | $1.0B |
| Q2 FY25 | $1.1B |
| Q3 FY25 | $1.1B |
| Q4 FY25 | $1.2B * |
| Q1 FY26 | $1.1B |
| Q2 FY26 | $1.2B |
| Q3 FY26 | $1.1B |
Data
| Q1 FY25 | $0.82 |
| Q2 FY25 | $1.49 |
| Q3 FY25 | $0.98 |
| Q1 FY26 | $0.87 |
| Q2 FY26 | $1.35 |
| Q3 FY26 | $1.43 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 FY24 | 15.9% |
| Q1 FY25 | 15.8% |
| Q2 FY25 | 20.2% |
| Q3 FY25 | 20.9% |
| Q4 FY25 | 17.3% |
| Q1 FY26 | 19.2% |
| Q2 FY26 | 21.1% |
| Q3 FY26 | 27.0% |
Data
| Q4 FY24 | $335.0M |
| Q1 FY25 | $208.0M |
| Q2 FY25 | $204.0M |
| Q3 FY25 | $253.0M |
| Q4 FY25 | $266.0M |
| Q1 FY26 | $251.0M |
| Q2 FY26 | $161.0M |
| Q3 FY26 | $379.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
Questions
How is NovaSeq X demand holding up?
Demand remained high more than three years after launch, with more than 95 placements in the quarter. The CEO said demand remains high as Illumina expands its workflow and multiomics capabilities.
Who is driving Illumina's growth?
Clinical markets, approximately 65% of sequencing consumables revenue, were the primary growth driver. Illumina says its technology is enabling clinical customers to expand sequencing-intensive applications.
What did Illumina launch this quarter?
Illumina launched StrataMap Spatial this summer, a sequencing-based spatial workflow. Over 300 million cells have been delivered to date and biopharma interest continues to grow.
What is Illumina's strategy beyond sequencing?
Its strategy is to deliver the highest quality insights for the lowest end-to-end cost, with a push into multiomics. The release also names integrating the SomaLogic business as a key factor.
What are the main risks to Illumina's plans?
The release cites SomaLogic integration, proteomics partner and customer relationships, tariffs, and its inclusion on China's Unreliable Entities List. Supply investment costs are also real, and Illumina is sharing some with customers.
Documents
SEC filing